ArticleNeuro-oncology advances

Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.

Souichi Suenobu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.